Company Overview
Snapshot
Founded in August 2021 by Yaniv Ben Haim, Nava Barit Ben David, and Ehud Jacobzon, Renalyte Medical operates with 1–10 employees. The company has secured two funding rounds and was featured on Israel’s Economy Channel in December 2025, highlighting its disruptive approach to renal care.
Business overview
Renalyte Medical is developing a fully implantable Renal Assist Device (RAD) designed to offer continuous, 24/7 blood filtration as an alternative to traditional hemodialysis. Its core technology utilizes a Safe-by-Design architecture with a venous-only approach to blood access, aiming to reduce surgical complications and long-term clinical risks. The company's solution automates internal fluid and toxin removal, seeking to transform End-Stage Renal Disease (ESRD) care from intermittent, clinic-based treatment to a continuous, internal solution. Renalyte operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving markets in North America, Europe, and Japan.
Strategic signal
In December 2025, Renalyte Medical was featured on Israel’s Economy Channel, where Danny Roup discussed the "obvious yet disruptive" nature of its fully implantable renal assist device. This media attention validates the company's innovative approach to addressing the $10 billion dialysis market and signals strong market interest in its continuous, internal filtration system as a paradigm shift for End-Stage Renal Disease care.
Log in to access full profile ›Company Intelligence Q&A
- What is Renalyte Medical's primary innovation?
- Renalyte Medical is developing a fully implantable Renal Assist Device (RAD) that provides continuous, 24/7 blood filtration, aiming to replace traditional hemodialysis. This system uses a venous-only blood access approach to minimize complications.
- When was Renalyte Medical founded and by whom?
- Renalyte Medical was founded in August 2021 by Yaniv Ben Haim, Nava Barit Ben David, and Ehud Jacobzon.
- Has Renalyte Medical received any grants?
- In August 2025, Renalyte Medical secured a grant from the Israel Innovation Authority for Proof of Concept (POC) validation.
- What is the strategic advantage of Renalyte Medical's technology?
- The company's technology aims to eliminate complications associated with arterial-venous pressure gradients by using a venous-only approach, thereby lowering the surgical barrier for implantation and reducing long-term clinical risk for End-Stage Renal Disease patients.
- What is the current development stage of Renalyte Medical's product?
- Renalyte Medical is currently advancing through pre-clinical milestones to validate Proof of Concept (POC) and system durability for its fully implantable Renal Assist Device.